Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Wednesday, November 14 at 11:20 AM (GMT), at the Jefferies 2012 Global Healthcare Conference, being held November 14-15, 2012 in London, England.
Mr. Christensen will also present at Piper Jaffray’s 24th Annual Healthcare Conference, on Tuesday November 27 at 4:30 PM (ET). The conference is being held November 27-28, at The New York Palace Hotel in New York City.
At both events, Mr. Christensen will provide a corporate update regarding the Company’s key value drivers – KALBITOR® (ecallantide) and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).
Both presentations will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The webcasts will also be available on the Dyax website for a limited period of time following the conferences.
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key value drivers are the KALBITOR® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).
Dyax developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.
The Company is currently developing products to expand its angioedema portfolio, including a diagnostic strategy to identify plasma kallikrein (bradykinin) mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for the prophylactic treatment of PKM angioedema.
KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 royalty and/or milestone bearing product candidates in various stages of clinical development, including three in Phase 3 trials.
Dyax is headquartered in Burlington, Massachusetts. For additional information about Dyax, please visit www.dyax.com.